Amelioration of sexual adverse effects in the early breast cancer patient

por Melisko, Michelle E., Goldman, Mindy, Rugo, Hope S.
Publicado 2010

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?

por Abel, Mary Kathryn, Melisko, Michelle E., Rugo, Hope S., Chien, A. Jo, Diaz, Italia, Levine, Julia K., Griffin, Ann, McGuire, Joseph, Esserman, Laura J., Borno, Hala T., Mukhtar, Rita A.
Publicado 2021

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

por Terranova-Barberio, Manuela, Pawlowska, Nela, Dhawan, Mallika, Moasser, Mark, Chien, Amy J., Melisko, Michelle E., Rugo, Hope, Rahimi, Roshun, Deal, Travis, Daud, Adil, Rosenblum, Michael D., Thomas, Scott, Munster, Pamela N.
Publicado 2020

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

por Freedman, Rachel A., Gelman, Rebecca S., Anders, Carey K., Melisko, Michelle E., Parsons, Heather A., Cropp, Anne M., Silvestri, Kelly, Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisin M., Moy, Beverly, Van Poznak, Catherine H., Blackwell, Kimberly L., Puhalla, Shannon L., Jankowitz, Rachel C., Smith, Karen L., Ibrahim, Nuhad, Moynihan, Timothy J., O’Sullivan, Ciara C., Nangia, Julie, Niravath, Polly, Tung, Nadine, Pohlmann, Paula R., Burns, Robyn, Rimawi, Mothaffar F., Krop, Ian E., Wolff, Antonio C., Winer, Eric P., Lin, Nancy U.
Publicado 2019